Thyroid Dysfunction Induced by Anti-PD-1 Therapy in Patients With Advanced Carcinoma

Study on the Correlation Between Thyroid Dysfunction Induced by Anti PD-1 Therapy and Prognosis in Patients With Advanced Carcinoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05593744

Enrollment

100

Registered

2022-10-25

Start date

2020-08-17

Completion date

2022-03-30

Last updated

2022-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma

Brief summary

In this study, we monitored patients with advanced malignant tumors who received anti-PD-1 therapy to observe the characteristic of anti-PD-1 therapy-induced thyroid dysfunction and its correlation with prognosis.

Interventions

OTHERno intervention

This is an observational study so not involved intervention

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Eighteen years or older * Confirmed diagnosis of malignancy * Received anti-PD-1 therapy

Exclusion criteria

* Thyroid malignancy or history of thyroid malignancy * Thyroid dysfunction before anti-PD-1 therapies * Previous ICIs treatment * Less than 2 cycles of anti-PD-1 treatment * No thyroid function monitoring during treatment * Known pituitary disease * Pregnancy.

Design outcomes

Primary

Measure	Time frame	Description
Progression-free survival	Through study completion, an average of 17 weeks	The time between initiation of anti-PD-1 therapy and disease progression or death, whichever came first.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026